Total revenue from operations for the quarter under review stood at ₹8,374.36 crore. It was ₹7,224.17 crore for the same period a year ago.
"Pola Pharma lnc Japan became a step-down subsidiary of the company with effect from January 1, 20l9. Accordingly, the results for the quarter include results of Pola Pharma Inc, and hence are not comparable with quarter ended June 30, 2018," the company said.
Shares of Sun Pharmaceutical Industries were trading at ₹441 per scrip on BSE, up 4.53 per cent from the precious close.